Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
The HIV-1 entry into host cells is a complex, multi-factors involved, and multi-step process. Especially, the attachment of HIV-1 envelope glycoprotein gp120 to the host cell receptor CD4 is the first key step during entry process, representing a promising antiviral therapeutic target. Among the HIV-1 attachment inhibitors blocking the interaction between gp120 and CD4 cells, BMS-378806 and NBD-556 are two representative small molecular chemical entities. Particularly, BMS-378806 and its derivatives are newly identified class of orally bioavailable HIV-1 inhibitors that interfere gp120-CD4 interaction. In this review, we focused on describing the structure-activity relationships (SARs), structural modifications, in vitro or even in vivo pharmacodynamics and pharmacokinetics of BMS-378806 and its analogues as HIV-1 gp120 attachment inhibitors. In addition, the brief SARs, structural modifications of NBD-556 and its derivatives targeting the "Phe-43 cavity" as CD4 mimics were also described.
['Liu|Tao|T|', 'Huang|Boshi|B|', 'Zhan|Peng|P|', 'De Clercq|Erik|E|', 'Liu|Xinyong|X|']
D000818:Animals D015704:CD4 Antigens D055808:Drug Discovery D015699:HIV Envelope Protein gp120 D006801:Humans D010879:Piperazines D011485:Protein Binding D054852:Small Molecule Libraries
HIV-1 BMS-378806 gp120 Attachment inhibitors NBD-556 AIDS Drug design